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Summary Introduction This multicenter, open-label, phase
II study was carried out to compare the efficacy and safety of
cilengitide (EMD 121974), a selective inhibitor of the cell-
surface integrins αVβ3 and αVβ5, with that of docetaxel in
patients with advanced non-small-cell lung cancer (NSCLC).
Methods Patients (n0140) with advanced NSCLC who had
failed first-line chemotherapy were randomized to cilengitide
240, 400, or 600 mg/m2 twice weekly, or docetaxel 75 mg/m2
once every 3 weeks for eight cycles. Non-progressing patients
could continue cilengitide for up to 1 year. The primary
endpoint was progression-free survival (PFS). No statistical
tests were performed since the study was exploratory in nature
and the number of patients enrolled was relatively small.
Results Median PFS was 54, 63, 63, and 67 days for
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cilengitide 240, 400, and 600mg/m2, and docetaxel 75mg/m2,
respectively. One-year survival rates were 13 %, 13 %, 29 %,
and 27 %, respectively. The response rate (partial response
only) with docetaxel was 15%. No responses were reported in
any cilengitide arm. The most frequent grade 3/4 treatment-
related adverse events in the docetaxel group were leukopenia
and neutropenia (experienced by 13 % of patients). Hemato-
logic toxicity of this severity did not occur in cilengitide-
treated patients. Conclusion With the highest dose of cilengi-
tide (600 mg/m2), median PFS and 1-year survival were sim-
ilar to those in patients treated with docetaxel 75 mg/m2 and
there were fewer grade 3/4 treatment-related adverse events.
Keywords Cilengitide . Integrin inhibitor . Docetaxel .
Non-small-cell lung cancer . Second-line treatment
Introduction
Lung cancer is the leading cause of cancer-related death
worldwide [1], and the majority of cases (85–90 %) are non-
small-cell lung cancer (NSCLC) [2]. Only 30–35 % of
patients with NSCLC present with sufficiently localized dis-
ease at diagnosis to attempt curative surgical resection (stages
IA and IB, IIA and IIB, and IIIA), and ~50 % of those who
undergo surgical resection will experience local or systemic
relapse. Thus ~80 % of all patients with lung cancer are
considered for chemotherapy at some point during the course
of their illness, and platinum-based combination regimens are
still considered standard of care for the majority of patients in
the first-line treatment of NSCLC [3].
At the time of this study (1999–2001), single-agent doce-
taxel (75 mg/m2 every 3 weeks) was the only approved
chemotherapy for the second-line treatment of advanced
NSCLC in the USA and Europe, having demonstrated longer
survival and better quality of life than best supportive care
alone [4, 5], and higher rates of 1-year survival than vinor-
elbine or ifosfamide [6]. Since then, although second-line
options have broadened, efforts to improve on the efficacy
of docetaxel, either by using an alternative agent or by com-
bining docetaxel with carboplatin, have not proved successful
[7, 8], and single-agent docetaxel remains one of the second-
line standards of care. However, docetaxel has only moderate
activity and is associated with non-hematologic and hemato-
logic toxicity, in particular, neutropenia and febrile neutrope-
nia [4, 6]. There is therefore a continuing need for new
therapies which are active in NSCLC and which have a
favorable safety profile giving them potential for use in
combination.
Cilengitide (EMD 121974) is the first compound in a new
class of targeted anticancer therapies – the integrin inhibitors –
to reach phase III clinical trial, and is currently in phase III in
glioblastoma. Integrins are heterodimeric transmembrane
receptors that play key roles in the interaction between cells,
adhesion to the extracellular environment, and cell migration
involved in angiogenesis and tumor development [9–12].
Cilengitide is a novel cyclized arginine–glycine–aspartic acid-
containing pentapeptide that selectively inhibits the cell-surface
integrins αVβ3 and αVβ5. Cilengitide is thought to act on
αVβ3- and αVβ5-expressing tumor cells both directly, by
deactivating signals involved in survival and growth, and indi-
rectly, by inhibiting angiogenesis and thereby tumor growth. It
blocks endothelial and tumor-cell adhesion, migration, and
differentiation [13–16].
The current clinical development program for cilengitide
includes glioblastoma (the phase III CENTRIC and phase II
CORE trials), head and neck cancer (phase II, ADVAN-
TAGE), and NSCLC (phase II, CERTO). The randomized
phase II trial in the first-line NSCLC setting (clinicaltrials.gov
NCT00842712) is investigating the effects of adding cilengi-
tide to cetuximab and platinum-based chemotherapy. Here we
report the first phase II study (EMD 121974–003) to examine
the effects of cilengitide in patients with NSCLC. It investi-
gated the efficacy and safety of three different doses of single-
agent cilengitide compared with docetaxel monotherapy as
second-line treatment in patients with advanced NSCLC who
had failed first-line chemotherapy.
This study was conducted in the period 1999–2001 and its
results were not published – in fact, the further clinical devel-
opment of cilengitide was put on hold. However, the growing
interest in anti-angiogenesis as a therapeutic approach promp-
ted renewed interest in the molecule and has resulted in the
extensive trial program noted above. In 2009, the results of
this early NSCLC trial were published in poster form [17], and
attracted interest. Moreover, this study remains relevant since
the comparator used, docetaxel, is still a standard of care in
second-line NSCLC, and efforts continue to find a drug with
which to combine it without adding unacceptable toxicity.
This study provides clinical evidence for the activity of cil-
engitide in NSCLC, complementing the preclinical in vivo
data suggesting antitumor efficacy and evidence from tumor
tissue that integrin overexpression may be of prognostic sig-
nificance in NSCLC [18].
Materials and methods
Study design
This was a multinational, multicenter, open-label, random-
ized, parallel-group, phase II study in patients with advanced
(stage IIIB and IV) NSCLC who had failed first-line chemo-
therapy. Patients were randomized to one of four treatment
groups: cilengitide 240, 400, or 600 mg/m2 twice weekly, or
docetaxel 75 mg/m2 once every 3 weeks for eight cycles. The
initial treatment period was 6 months, but patients whose
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tumor growth was controlled by cilengitide could continue
therapy for an additional 6 months, to a maximum treatment
period of 1 year. On completion or withdrawal from the study,
all patients were followed until the end of the study to assess
overall survival (OS).
The primary endpoint was progression-free survival
(PFS). Secondary endpoints were response rate, OS, safety,
and tolerability.
Patients
Both genders were eligible for inclusion, but women had to be
postmenopausal or infertile. Other eligibility criteria were: (i)
age ≥18 years (≥19 years in Austria); (ii) cytologically or
histologically confirmed advanced NSCLC; (iii) at least one
measurable/evaluable lesion according to Response Evaluation
Criteria In Solid Tumors (RECIST) not located within the area
of any previous radiation; (iv) failure of first-line therapy
(defined as disease progression during first-line therapy or after
its discontinuation); (v) life expectancy ≥12 weeks; (vi) only
one previous chemotherapy regimen (one to six courses); (vii)
Karnofsky performance status ≥70%; and (viii) adequate renal
function (creatinine <2×upper limit of normal, ULN), hepatic
function (total bilirubin <2×ULN and serum transaminases
≤3×ULN, or ≤5×ULN in patients with known liver metasta-
ses), and hematologic function (granulocytes ≥1500/mm3, pla-
telets ≥100,000/mm3, and hemoglobin ≥10 g/dL).
Exclusion criteria were: (i) pregnancy or breast-feeding;
(ii) chemotherapy and/or radiotherapy treatment or major
surgery within 4 weeks of study entry; (iii) previous treat-
ment with docetaxel or anti-angiogenic therapy; (iv) history
of brain metastases; (v) history of cerebrovascular accident
or transient ischemic attack; clinically significant cardiac or
cardiovascular abnormalities (New York Heart Association
III/IV), or unstable angina or arrhythmias (Lown grading sys-
tem for cardiac arrhythmias grade IV) requiring treatment; (vi)
bypass surgery within 6 months prior to treatment; (vii) known
active infection with human immunodeficiency virus, hepatitis
B virus, or hepatitis C virus; or (viii) history of paclitaxel or
docetaxel allergy.
The protocol was approved before the start of the study by
the relevant Independent Ethics Committees in the participating
institutions. The study was performed in accordance with the
Declaration of Helsinki, Good Clinical Practice guidelines, and
applicable regulatory requirements. Written informed consent
was obtained from all patients at the screening visit.
Treatment
Patients were randomized to one of three cilengitide doses
(240, 400, or 600 mg/m2) twice weekly as a 1-hour intrave-
nous infusion or docetaxel 75 mg/m2 as a 1-hour intravenous
infusion once per cycle over 8 cycles. A cycle was defined as a
treatment period of 3 weeks. Steroid prophylaxis was given to
patients in the docetaxel group. The doses of cilengitide
chosen for study were based on experience in a phase I trial
in which the amount of drug administered was escalated from
30 mg/m2 to 600 mg/m2 without encountering unacceptable
toxicity. In the absence of a defined maximum tolerated dose
for cilengitide, the three highest dose levels used in phase I (ie,
240, 400, and 600 mg/m2) were chosen for comparison with
docetaxel in this randomized phase II trial.
Assessments
PFS was defined as the time interval between the date of
randomization and the date of disease progression or death,
whichever occurred first. Tumor response was assessed accord-
ing to the first version of RECIST [19], based on the size of the
target lesions, as determined by computed tomography and/or
magnetic resonance imaging. Response rate was defined as the
sum of the rates of complete response (CR) and partial response
(PR) per treatment arm. Tumor growth control was defined as
the sum of the CR, PR, and stable disease (SD) rates. OS was
defined as the time from the start of study drug administration
until death. Safety was evaluated by laboratory assessments,
physical measurements (heart rate; systolic/diastolic blood
pressure; body temperature; body weight; status according to
the Karnofsky Performance Index; physical examination elec-
trocardiogram [ECG]), and monitoring of adverse events (AEs)
which were graded according to the National Cancer Institute
(NCI) Common Toxicity Criteria (CTC) system version 2. The
AE data were re-analyzed in March 2011 using MedDRA®
Terminology Version 10.0.
Statistical analysis
Given the relatively small number of patients in each treatment
arm and the exploratory nature of the trial, it was not intended
that tests of statistical significance (or subgroup analyses)
would be undertaken. The study was not powered to demon-
strate non-inferiority. Results were interpreted with descriptive
statistics using SAS version 8.
The primary efficacy analysis was performed on an
intention-to-treat (ITT) basis, including all randomized
patients, and a Kaplan–Meier estimate of survival probabilities
was constructed. The safety analyses included all randomized
patients who had taken at least one dose of a study drug.
Results
Patients
In total, 140 patients from 30 centers in seven countries
(Austria, Belgium, France, Germany, the Netherlands,
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Spain, and the UK) were randomized and included in the
study (ITT analysis). The first patient was enrolled in Novem-
ber 1999 and the study was completed in October 2001. Three
patients did not receive any study medication (one in the
cilengitide 240 mg/m2 group and two in the docetaxel group),
meaning that 137 patients were included in the safety analysis.
Patient baseline characteristics are shown in Table 1: the
majority was male (67 %), their mean age was 60.2 years
(range 33–80 years), and 96% had stage IV disease. Given the
date of the study, histology data were not documented as
rigorously as would be the case in current trials (and 46 %
of tumors were not specified in this regard). However, from
the data available, the predominant histology across treatment
groups was adenocarcinoma. The majority of patients had
received platinum-based regimens as first-line therapy. The
proportion of patients who had had tumor-related surgery was
higher among patients randomized to docetaxel and 600mg/m2
cilengitide than in those randomized to lower doses of the
integrin inhibitor. Overall, however, there were no clinically
important differences between the treatment groups with regard
to baseline characteristics.
Treatment
Median (range) duration of treatment was 41 (4–165), 50 (15–
155), and 60 (1–253) days with cilengitide 240, 400, and
600 mg/m2, respectively, and 48 (1–163) days with docetaxel.
The main reason for study discontinuation was progressive
disease (93 patients, 66 %), which occurred more frequently
with cilengitide (71 % of patients) than docetaxel (50 %).










Male/female, n (%) 25/10 (71/29) 25/10 (71/29) 22/14 (61/39) 22/12 (65/35) 94/46 (67/33)
Mean age (range), yrs 62.5 (45.0–80.0) 57.8 (33.0–77.0) 59.3 (41.0–76.0) 61.2 (42.0–79.0) 60.2 (33.0–80.0)
Karnofsky PS n (%)
100 % 4 (11) 5 (14) 5 (14) 5 (15) 19 (14)
90 % 8 (23) 14 (40) 12 (33) 10 (29) 44 (31)
80 % 17 (49) 12 (34) 12 (33) 12 (35) 53 (38)
70 % 6 (17) 4 (11) 7 (19) 7 (21) 24 (17)
Tumor stage, n (%)
IIIB 1 (3) 2 (6) 0 3 (9) 6 (4)
IV 34 (97) 33 (94) 36 (100) 31 (91) 134 (96)
Histologya, n (%)
Adenocarcinoma 14 (40) 12 (34) 12 (33) 9 (26) 47 (34)
Squamous 2 (6) 4 (12) 4 (12) 8 (24) 18 (13)
Other 4 (11) 2 (6) 2 (6) 2 (6) 10 (7)
Unknown 15 (43) 17 (49) 18 (50) 15 (44) 65 (46)
Prior chemotherapy, n (%)
Platinum based 25 (71) 25 (71) 28 (78) 23 (68) 101 (72)
Non-platinum 10 (29) 10 (29) 8 (22) 11 (32) 39 (28)
Prior radiation, n (%) 12 (34) 12 (34) 11 (31) 15 (44) 50 (36)
Tumor-related surgery, n (%) 6 (17) 8 (23) 14 (39) 12 (35) 40 (29)
a Given the date of the study, histology was not performed as rigorously as would be the case in current trials
Karnofsky PS, Karnofsky performance status









Median PFS, days [95 % CI] 54 [43–64] 63 [53–66] 63 [42–67] 67 [61–123]
Median OS, days [95 % CI] 173 [81–197] 117 [92–209] 181 [90–326] 194 [135–298]
1-year survival rate, % [95 % CI] 13 [1.2–24.4] 13 [0.4–25.5] 29 [12.3–46.5] 27 [10.4–43.4]
CI, confidence interval; OS, overall survival; PFS, progression-free survival
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There were no important differences between the treatment
groups with respect to the percentage of patients who withdrew
due to AEs (~14 % in the cilengitide groups vs ~12 % in the
docetaxel group).
Fig. 1 Progression-free survival (a) and overall survival (b) of non-small-cell lung cancer patients treated with cilengitide 240, 400, or 600 mg/m2,
or docetaxel 75 mg/m2
Table 3 Tumor response
rates of intention-to-treat
population
aTwo of these five partial
responses were not confirmed
according to Response Evaluation










Complete response, n 0 0 0 0
Partial response, n (%) 0 0 0 5a (15)
Stable disease, n (%) 7 (20) 3 (9) 7 (19) 11 (32)
Progressive disease, n (%) 17 (49) 26 (74) 23 (64) 12 (35)
Response rate, % 0 0 0 15
Tumor growth control, % 20 9 19 47
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Eight patients (6 %) completed eight cycles of treatment:
one patient (3 %) in the cilengitide 240 mg/m2 group, two
patients (6 %) in the 600 mg/m2 group, and five patients
(15 %) in the docetaxel group. One patient (3 %) in the
cilengitide 600 mg/m2 group completed 11 cycles of
treatment.
Efficacy
Median PFS (Table 2, Figure 1a) was longer with cilengitide
400 and 600 mg/m2 (63 days) than with cilengitide 240 mg/
m2 (54 days, 95 % CI 43–64) and similar to that with
docetaxel (67 days, 95 % CI 61–123). Median OS (Table 2,
Figure 1b) was shorter with cilengitide 400 mg/m2
(117 days) than with cilengitide 240 mg/m2 (173 days,
95 % CI 81–197) or 600 mg/m2 (181 days, 95 % CI 90–
326), or docetaxel (194 days, 95 % CI 135–298). Median
OS was similar for cilengitide 600 mg/m2 and docetaxel.
The cilengitide 600 mg/m2 and docetaxel arms had similar
1-year survival rates: 29 % and 27 %, respectively (Table 2).
No patient had a CR, and only five patients (all in the
docetaxel group) were reported as having a PR (Table 3).
In two of these five cases, responses were not confirmed
according to RECIST. SD was also achieved by more
patients in the docetaxel group than in the cilengitide groups
(Table 3).
Safety
AEs of any degree of severity were experienced by 98 % of
patients. Grade 3/4 treatment-related AEs were more common
among docetaxel-treated patients (Table 4): 13 (41 %) expe-
rienced more than one AE, compared with two patients (6 %)
in the 240 mg cilengitide arm and four patients (11 %) in each
cilengitide group receiving the higher doses (Table 4). The
incidence of grade 3/4 nausea and fatigue was comparable
across treatment arms, but hematologic toxicity was more
common with docetaxel. Table 5 shows the frequency of
grade 3/4 treatment-emergent AEs regardless of the relation-
ship to the investigational agents. Sixteen percent of docetaxel-
treated patients experienced grade 3/4 leukopenia and neutro-
penia. Hematologic toxicity of this severity did not occur with
cilengitide.
Fifteen patients died during the study due to progressive
disease, pneumonia, dysuria, dyspnea, worsening of chronic
obstructive pulmonary disease, or thrombocytopenia (three,
five, and four patients in the cilengitide 240, 400, and
600 mg/m2 groups, respectively, and three patients in the
docetaxel group). Only two deaths were classified as related
to treatment. One was a case of tumor progression (in the
cilengitide 240 mg/m2 arm) and one a case of thrombocytope-
nia (in a patient treated with 600 mg/m2 cilengitide).
There were generally no clinically significant differences
between the treatment groups with respect to vital signs (blood
Table 4 Grade 3/4 treatment-
related adverse events
aUnless otherwise stated, grade
3/4 treatment-related AEs
occurring in two or more
patients in any treatment group
bOne patient did not
receive study drug
cTwo patients did not
receive study drug









adverse event, n (%)
2 (6) 4 (11) 4 (11) 13 (41)
Nausea 1 (3) 0 0 2 (6)
Chest pain 0 2 (6) 0 0
Dyspnea 1 (3) 1 (3) 0 1 (3)
Leukopenia 0 0 0 4 (13)
Neutropenia 0 0 0 4 (13)
Fatigue 0 1 (3) 1 (3) 1 (3)
Table 5 Grade 3/4 treatment-
emergent adverse eventsa
aThese data were re-analyzed in
March 2011 according to Med-
DRA version 10.0. Adverse
events (AEs) are ordered by fre-












Patients with any AE, n (%) 21 (61.8) 26 (74.3) 27 (75.0) 24 (75.0)
Dyspnea 8 (23.5) 10 (28.6) 12 (33.3) 5 (15.6)
Asthenia 1 (2.9) 1 (2.9) 0 5 (15.6)
Neutropenia 0 0 0 5 (15.6)
Leukopenia 2 (5.9) 0 0 4 (12.5)
Pneumonia 1 (2.9) 0 1 (2.8) 4 (12.5)
Tumor pain 0 2 (5.7) 2 (5.6) 1 (3.1)
Chest pain 2 (5.9) 4 (11.4) 1 (2.8) 0
Pleural effusion 2 (5.9) 2 (5.7) 2 (5.6) 0
Back pain 3 (8.8) 3 (8.6) 1 (2.8) 0
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pressure and heart rate), ECG findings, or laboratory assess-
ments. A higher proportion of docetaxel-treated patients
(19 %) had abnormal neutrophil counts compared with
cilengitide-treated patients (9 %, 3 %, and 14 %, in the 240,
400, and 600 mg/m2 groups, respectively).
Discussion
Integrin inhibitors are a novel class of anticancer agents, being
developed in response to the continuing need for therapies that
target different components of the tumorigenic process [10].
Integrins enable binding between tumor cells and the extra-
cellular matrix, and integrin signaling regulates tumor cell
migration, invasion, proliferation, and survival. Integrins are
also involved in angiogenesis.
Surgical carcinoma specimens show expression of αVβ3
and αVβ5 integrins by tumor and stromal cells and in the
vasculature of lung tumors [20], confirming earlier evidence
that integrin inhibition is a rational therapeutic strategy in
NSCLC [21]. PRs to single-agent cilengitide have been
reported in phase I and II studies in patients with glioblastoma,
where cilengitide has been more extensively studied [22, 23].
This phase II trial was the first to assess the efficacy, safety,
and tolerability of cilengitide in the treatment of NSCLC.
Median PFS at higher doses of single-agent cilengitide (400
and 600 mg/m2) was similar to that with single-agent doce-
taxel, which remains a standard of care and a relevant com-
parator in clinical trials [8]. One-year survival rates were
similar for cilengitide 600 mg/m2 (29 %) and docetaxel
(27 %). So too was median OS (194 days for docetaxel and
181 days for cilengitide 600 mg/m2). Interestingly – and
supporting the relevance of this study – the median 194-day
OS we report with 3-weekly docetaxel closely matches the
median 189-day OS in a meta-analysis of data from five
second-line docetaxel trials involving 433 patients [24].
No CRs were seen with either cilengitide or docetaxel. The
PR rate with docetaxel was 15 % while no cilengitide-treated
patient had a PR. The PR rate with docetaxel seen in this study
is similar to the 13–22 % rates reported in other monotherapy
studies of the taxane in advanced NSCLC [25–27].
Although the median PFS of single-agent cilengitide
600 mg/m2 was similar to that of docetaxel, there were impor-
tant differences in the toxicity profiles of the two agents. The
safety profile of cilengitide in terms of grade 3/4 treatment-
related AEs was superior to that of docetaxel: while 16 % of
docetaxel-treated patients experienced grade 3/4 leukopenia
and neutropenia, no such cases were reported in cilengitide-
treated patients. Indeed, cilengitide was well tolerated general-
ly in the present trial, and this has remained the case even at the
substantially higher doses used in subsequent studies, such as
those in which patients with recurrent glioblastoma received up
to 2400 mg/m2 of the drug [23, 28]. Importantly, the AEs with
cilengitide showed little overlap with those of docetaxel, sug-
gesting that the two agents might be combined, either simul-
taneously or sequentially.
This study was conducted 10 years ago, when require-
ments for histology were less rigorous than today, and trials
in non-selected populations of NSCLC patients were rou-
tine. The direct applicability of its results to current man-
agement is therefore limited. However, the study remains
important in showing the potential of cilengitide as a well-
tolerated treatment option in advanced NSCLC and supports
its development as a combination partner in therapy. An
ongoing phase II study (CERTO) is investigating cilengitide
in combination with platinum-based chemotherapy and the
growth factor receptor inhibitor cetuximab as first-line treat-
ment for advanced NSCLC. Recent results from the safety
run-in phase of this trial have shown that cilengitide (at doses
of 1000 or 2000 mg twice weekly) combined with standard
therapy was well tolerated with no unexpected AEs and no
dose-limiting toxicities [29].
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